SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer

• Published in: Genomics (San Diego, Calif.) Calif.), 2023-09, Vol.115 (5), p.110667-110667, Article 110667
• Main Authors: Lu, Xin-Sheng, Huang, Meng-Long, Chen, Li-Bo, Liu, Shu-Cheng, Huang, Zhong-Xin, Liu, Shi-Min
• Format: Article
• Language: English
• Subjects: Bladder cancer; lncRNA PCAT29; miR-141; SCARA5
• ISSN: 0888-7543; 1089-8646
• DOI: 10.1016/j.ygeno.2023.110667

Scavenger receptor class A, member 5 (SCARA5) has been identified a novel tumor suppressor in several cancers. However, the functional and underlying mechanism of SCARA5 in bladder cancer (BC) need investigation. Here, we found SCARA5 expression was downregulated in both BC tissues and cell lines. Low SCARA5 in BC tissues was associated with a shorter overall survival. Moreover, SCARA5 overexpression reduced BC cell viability, colony formation, invasion, and migration. Further investigation demonstrated that the expression of SCARA5 was negatively regulated by miR-141. Furthermore, the long non-coding RNA prostate cancer associated transcript 29 (PCAT29) inhibited the proliferation, invasion, and migration of BC cells by sponging miR-141. Luciferase activity assays revealed that PCAT29 targeted miR-141 and miR-141 targeted SCARA5. In conclusion, SCARA5, as a downstream factor of the PCAT29/miR-141 axis, inhibited the proliferation, migration, and invasion of BC cells. These findings provide novel insights into the detailed molecular mechanisms of BC development. •PCAT29 was downregulated in BC and low PCAT29 was correlated with poor prognosis.•PCAT29 suppressed proliferation, attenuated invasive and migrative capacity of BC cells partly via miR-432-5p.•MiR-432-5p promoted proliferation, invasive and migrative capacity of BC cells at least partly dependent by inhibiting Tesr.